<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.0//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/static/PubMed.dtd">
<ArticleSet><Article><Journal><PublisherName></PublisherName><JournalTitle>Journal of Research in Medical Sciences</JournalTitle><Issn>1735-1995</Issn><Volume>17</Volume><Issue>7</Issue><PubDate PubStatus="epublish"><Year>2012</Year><Month>05</Month><Day>15</Day></PubDate></Journal><ArticleTitle>The effect of  oral l-carnitine on the endothelial function of the hemodialysis patients</ArticleTitle><FirstPage>8359</FirstPage><LastPage>8359</LastPage><Language>EN</Language><AuthorList><Author><FirstName>Mohammad Reza</FirstName><LastName>Sabri</LastName></Author><Author><FirstName>Farnaz</FirstName><LastName>Fahimi</LastName></Author><Author><FirstName>Soheila</FirstName><LastName>Hajialiasgar</LastName><Affiliation>Department of Radiology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran. s_asgary@yahoo.com</Affiliation></Author><Author><FirstName>Abbas</FirstName><LastName>Etminan</LastName></Author><Author><FirstName>Sarir</FirstName><LastName>Nazemi</LastName></Author><Author><FirstName>Farzaneh</FirstName><LastName>Salehi</LastName></Author></AuthorList><History><PubDate PubStatus="received"><Year>2012</Year><Month>05</Month><Day>15</Day></PubDate><PubDate PubStatus="accepted"><Year>2012</Year><Month>05</Month><Day>15</Day></PubDate></History><Abstract>BACKGROUND: Atherosclerosis is the leading cause of death in hemodialysis patients. These patients are also highly prone to L-carnitine deficiency due to kidney disease. In this clinical trial, we investigated the effect of oral L-carnitine on the endothelial function of these patients. METHODS: We studied 31 adult chronic hemodialysis patients in our center and divided them into two groups, a group of 20 patients who received 1500 mg/dialysis interval (every other day) oral L-carnitine and a control group of 11 patients who received placebo for one month. Ultrasonographic measurement of flow mediated dilation and carotid intima media thickness were performed before and after one month of L-carnitine and Placebo therapy.RESULTS: This study showed that after one month of L-carnitine or placebo therapy there was no significant improvement in flow mediated dilation ( p = 0.80, p=0.59 respectively) or decrease in carotid intima media thickness ( p = 0.12, p = 0.50 respectively).&amp;nbsp; CONCLUSIONS: Our study revealed that one month oral L-carnitine therapy does not improve endothelial function in hemodialysis patients. Long term studies with a large sample size using intravenous form and higher doses of the drug are required to clarify the questionable role of L-Carnitine in hemodialysis patients.KEYWORDS: Flow-mediated-dilation, Carotid-intima-media-thickness, Endothelial Dysfunction, Chronic Renal Failure, L-carnitine</Abstract></Article></ArticleSet>
